Pieris Pharmaceuticals (PIRS)
(Delayed Data from NSDQ)
$11.72 USD
+0.12 (1.03%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $11.78 +0.06 (0.51%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Pieris Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 43 | 26 | 31 | 29 | 46 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 43 | 26 | 31 | 29 | 46 |
Selling & Adminstrative & Depr. & Amort Expenses | 73 | 69 | 83 | 63 | 73 |
Income After Depreciation & Amortization | -30 | -43 | -52 | -34 | -27 |
Non-Operating Income | 5 | 10 | 6 | -3 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -25 | -33 | -46 | -37 | -25 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -25 | -33 | -46 | -37 | -25 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -25 | -33 | -46 | -37 | -25 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -28 | -41 | -49 | -32 | -27 |
Depreciation & Amortization (Cash Flow) | 2 | 3 | 2 | 2 | 1 |
Income After Depreciation & Amortization | -30 | -43 | -52 | -34 | -27 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 90.06 | 74.17 | 64.55 | 54.48 | 50.63 |
Diluted EPS Before Non-Recurring Items | -0.12 | -0.45 | -0.71 | -0.68 | -0.56 |
Diluted Net EPS (GAAP) | -0.27 | -0.45 | -0.71 | -0.68 | -0.56 |
Fiscal Year end for Pieris Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 1.30 | 19.52 | 20.06 | 1.94 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 1.30 | 19.52 | 20.06 | 1.94 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 5.80 | 31.33 | 17.99 | 17.44 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -4.50 | -11.81 | 2.07 | -15.50 |
Non-Operating Income | NA | -0.08 | 1.06 | 1.91 | 2.33 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -4.58 | -10.75 | 3.98 | -13.18 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -4.58 | -10.75 | 3.98 | -13.18 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -4.58 | -10.75 | 3.98 | -13.18 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 105.78 | 98.85 | 87.93 | 74.52 |
Diluted EPS Before Non-Recurring Items | NA | -0.05 | -0.11 | 0.05 | -0.18 |
Diluted Net EPS (GAAP) | NA | -0.03 | -0.11 | 0.05 | -0.18 |